A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.

Trial Profile

A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Azacitidine (Primary) ; Ruxolitinib (Primary)
  • Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions
  • Acronyms PHAZAR
  • Most Recent Events

    • 01 Aug 2018 Planned End Date changed from 4 Jun 2018 to 31 Jul 2020.
    • 01 Aug 2018 Status changed from completed to recruiting.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top